U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29FO5
Molecular Weight 392.4611
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE

SMILES

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H29FO5
Molecular Weight 392.4611
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline.
1999 Apr
Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression.
1999 Apr
Inhibition of heat shock factor activity prevents heat shock potentiation of glucocorticoid receptor-mediated gene expression.
1999 Dec
Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach.
1999 Dec
Platelet-activating factor receptor mRNA is localized in eosinophils and epithelial cells in rat small intestine: regulation by dexamethasone and gut flora.
1999 Jul
Differential regulation of peptide alpha-amidation by dexamethasone and disulfiram.
1999 Jun
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.
1999 Jun
A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.
1999 Mar
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes.
1999 May 15
Dexamethasone therapy increases infection in very low birth weight infants.
1999 Nov
Antenatal dexamethasone suppresses tumor necrosis factor-alpha expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
1999 Nov
Antenatal dexamethasone improves atrial natriuretic peptide receptors in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000
Immune abnormalities in aneurysmal subarachnoid haemorrhage patients: relation to delayed cerebral vasospasm.
2000 Apr
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Effects of dexamethasone on mitogen-activated protein kinases in mouse macrophages: implications for the regulation of 85 kDa cytosolic phospholipase A(2).
2000 Aug 15
Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat.
2000 Dec
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
2000 Dec 15
Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage.
2000 Feb
Dexamethasone blocks sepsis-induced protection of the heart from ischemia reperfusion injury.
2000 Jan
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
2000 Mar
Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.
2000 Mar
Corticosteroids and cognitive function in humans: methodological considerations.
2000 May-Jun
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.
2000 Sep
Intractable nausea attributable to isolated deficiency of adrenocorticotropic hormone: prompt resolution after administration of glucocorticoid.
2000 Sep-Oct
A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide.
2001 Feb
The clinical impact of metabolic bone disease in coeliac disease.
2001 Jan
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.
2001 Jan
Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group.
2001 Jan-Feb
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
2009 Apr 15
Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.
2012 Jun
Patents

Sample Use Guides

In Vivo Use Guide
One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In mild disease, drops may be used up to four to six times daily.
Route of Administration: Otic; Oral; Intravenous; Intramuscular; Intra-articular; Topical
In Vitro Use Guide
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:43:44 UTC 2019
Edited
by admin
on Mon Oct 21 20:43:44 UTC 2019
Record UNII
7S5I7G3JQL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE
EMA EPAR   EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ISV-305
Code English
DEXASONE
Brand Name English
DEXAMETHASONE [MART.]
Common Name English
DEXAMETHASONE COMPONENT OF TOBRADEX ST
Brand Name English
DEXAMETHASONE [WHO-DD]
Common Name English
DEXAMETHASONE [ORANGE BOOK]
Common Name English
DEXAMETHASONE COMPONENT OF CIPRODEX
Brand Name English
DEXAMETHASONE [USP-RS]
Common Name English
LOVERINE
Brand Name English
GAMMACORTEN
Common Name English
DEXAMETASONE
Common Name English
MAXIDEX
Brand Name English
SUPERPREDNOL
Common Name English
FORTECORTIN
Brand Name English
DEXAMETHASONE ACETATE IMPURITY A [EP]
Common Name English
DEXASPORIN COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [USP]
Common Name English
IMPURITY A [WHO-IP]
Common Name English
DEXAMETHASONE [JAN]
Common Name English
(11.BETA.,16.ALPHA.)-9-FLUORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DEXA-SINE
Brand Name English
DEXONE
Brand Name English
MAXITROL COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONUM [WHO-IP LATIN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXASPORIN
Brand Name English
DEXAMETHASONE [EP]
Common Name English
NSC-34521
Code English
DEXAMETHASONE [EMA EPAR]
Common Name English
FLUORMETHYLPREDNISOLONE
Common Name English
AEROSEB-DEX
Brand Name English
DEXAMETHASONE [INN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXACIDIN
Brand Name English
BETAMETHASONE IMPURITY A [EP]
Common Name English
DEXASITE
Brand Name English
DEXAMONOZON
Brand Name English
DEXAMETHASONE COMPONENT OF TOBRADEX
Brand Name English
DEXAMETHASONE [VANDF]
Common Name English
DEXAPOS
Brand Name English
LUXAZONE
Brand Name English
DECADRON
Brand Name English
DEXYCU
Brand Name English
TOBRADEX ST COMPONENT DEXAMETHASONE
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17,21-TRIHYDROXY-16-METHYL-,(11.BETA.,16.ALPHA.)-9-FLUORO- 11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE- 3,20-DIONE
Common Name English
DEXACIDIN COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [WHO-IP]
Common Name English
TOBRADEX COMPONENT DEXAMETHASONE
Brand Name English
HEXADROL
Brand Name English
DECADERM
Brand Name English
OZURDEX
Brand Name English
ISOPTO-DEX
Brand Name English
CIPRODEX COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [HSDB]
Common Name English
DEXAMETHASONE [MI]
Common Name English
VISUMETAZONE
Common Name English
HEXADECADROL
Common Name English
DEXACORTAL
Brand Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DECASPRAY
Brand Name English
MILLICORTEN
Common Name English
DEXACORTIN
Brand Name English
DEXAMETHASONE COMPONENT OF MAXITROL
Brand Name English
DEXTENZA
Brand Name English
16.ALPHA.-METHYL-9.ALPHA.-FLUOROPREDNISOLONE
Common Name English
APHTHASOLONE
Common Name English
OTO-104
Code English
DEXAMETHASONE [GREEN BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC R01AD03
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 522.540
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 520.540
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 520.540A
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QD10AA03
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S01BA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S03BA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC D07XB05
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QR01AD03
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QD07AB19
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QH02AB02
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 17.2
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
NCI_THESAURUS C521
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
NDF-RT N0000175576
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS01CB01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QD07XB05
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC C05AA09
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 520.540C
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC R01AD53
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
EMA ASSESSMENT REPORTS OZURDEX (AUTHORIZED: MACULAR EDEMA)
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS02BA06
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
EMA ASSESSMENT REPORTS ORZUDEX (AUTHORIZED: UVEITIS)
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QD07CB04
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S03CA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S02BA06
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS03CA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S01CA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS01BA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
FDA ORPHAN DRUG 115298
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S02CA06
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QR01AD53
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
LIVERTOX 288
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 522.542
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
NCI_THESAURUS C267
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS03BA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC D07AB19
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS01CA01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QC05AA09
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
NDF-RT N0000175450
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC S01CB01
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
EMA ASSESSMENT REPORTS NEOFORDEX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC H02AB02
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QA01AC02
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 520.540B
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC A01AC02
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC D10AA03
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
EU-Orphan Drug EU/3/10/763
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 524.1484G
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QH02BX90
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
CFR 21 CFR 520.563
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
FDA ORPHAN DRUG 626318
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-ATC D07CB04
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
WHO-VATC QS02CA06
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
Code System Code Type Description
WIKIPEDIA
DEXAMETHASONE
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
LactMed
50-02-2
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
PUBCHEM
5743
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
NCI_THESAURUS
C422
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
HSDB
50-02-2
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
MERCK INDEX
M4215
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY Merck Index
RXCUI
3264
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY RxNorm
DRUG BANK
DB01234
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY Description: Colourless crystals or a white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS.Category: Adrenoglucocorticoid. Storage: Dexamethasone should be kept in a tightly closed container, protected from light.
MESH
D003907
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
IUPHAR
2768
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
EPA CompTox
50-02-2
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
ECHA (EC/EINECS)
200-003-9
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
EVMPD
SUB07017MIG
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
CAS
50-02-2
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
ChEMBL
CHEMBL384467
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
INN
816
Created by admin on Mon Oct 21 20:43:44 UTC 2019 , Edited by admin on Mon Oct 21 20:43:44 UTC 2019
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> SUBSTRATE
TARGET -> AGONIST
BINDING
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
PARENT -> IMPURITY
In the chromatogram obtained with solution (1): the area of any peak corresponding to impurity A, when multiplied by a correction factor of 0.75, is not greater than 5 times the area of the principal peak obtained with solution (4) (0.5%).
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC